Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 355-362

  Bhujwalla, Zaver M ^a   Artemov, Dmitri ^a   Natarajan, Kshama ^a   Solaiyappan, Meiyappan ^a   Kollars, Peggy ^a   Kristjansen, Paul E G ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE;

ANIMAL CELL; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INVASION; CONTRAST ENHANCEMENT; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SOLID TUMOR; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CONTRAST MEDIA; CYCLOHEXANES; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RATS; SESQUITERPENES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037242284     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175: 409-416, 1972.
2. Denekamp, J., Dasu, A., and Waites, A. Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Adv. Enzyme Regul., 38: 281-299, 1998.
3. Harris, A. L., Zhang, H., Moghaddam, A., Fox, S., Scott, P., Pattison, A., Gatter, K., Stratford, I., and Bicknell, R. Breast cancer angiogenesis - new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Res. Treat., 38: 97-108, 1996.
4. Auerbach, W., and Auerbach, R. Angiogenesis inhibition: a review. Pharmacol. Ther., 63: 265-311, 1994.
5. Gillies, R. J., Bhujwalla, Z. M., Evelhoch, J., Garwood, M., Neeman, M., Robinson, S. P., Sotak, C, H., and Van der Sanden. B. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia, 2: 139-151, 2000.
6. Brasch, R., Pham, C., Shames, D., Roberts, T., van Dijke, K., van Bruggen, N., Mann, J., Ostrowitzki, S., and Melnyk, O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J. Magn. Reson. Imaging, 7: 68-74, 1997.
7. Gossmann, A., Helbich, T. H., Kuriyama, N., Ostrowitzki, S., Roberts, T. P., Shames, D. M., van Bruggen, N., Wendland, M. F., Israel, M. A., and Brasch, R. C. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J. Magn. Reson. Imaging, 15: 233-240, 2002.
8. Gossmann, A., Helbich, T. H., Mesiano, S., Shames, D. M., Wendland, M. F., Roberts, T. P., Ferrara, N., Jaffe, R. B., and Brasch, R. C. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am. J. Obstet. Gynecol., 183: 956-963, 2000.
9. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (Lond.), 348: 555-557, 1990.
10. Taki, T., Ohnishi, T., Arita, N., Hiraga, S., Saitoh, Y., Izumoto, S., Mori, K., and Hayakawa, T. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J. Neurooncol., 19: 251-258, 1994.
11. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer, 69: 212-216, 1994.
12. Kragh, M., Spang-Thomsen, M., and Kristjansen, P. E. Time until initiation of tumor growth is an effective measure of the anti-angiogenic effect of TNP-470 on human glioblastoma in nude mice. Oncol. Rep., 6: 759-762, 1999.
13. Kin, M., Torimura, T., Ueno, T., Nakamura, T., Ogata, R., Sakamoto, M., Tamaki, S., and Sata, M. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int. J. Oncol., 16: 375-382, 2000.
14. Ueda, N., Kamata, N., Hayashi, E., Yokoyama, K., Hoteiya, T., and Nagayama, M. Effects of an anti-angiogenic agent, TNP-470, on the growth of oral squamous cell carcinomas. Oral Oncol., 35: 554-560, 1999.
15. Castronovo, V., and Belotti, D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur. J. Cancer, 32A: 2520-2527, 1996.
16. Bhargava, P., Marshall, J. L., Rizvi, N., Dahut, W., Yoe, J., Figuera, M., Phipps, K., Ong, V. S., Kato, A., and Hawkins, M. J. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res., 5: 1989-1995, 1999.
17. Griffith, E. C., Su, Z., Turk, B. E., Chen, S., Chang, Y. H., Wu, Z., Biemann, K., and Liu, J. O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol., 4: 461-471, 1997.
18. Sin, N., Meng, L., Wang, M. Q., Wen, J. J., Bornmann, W. G., and Crews, C. M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA, 94: 6099-6103, 1997.
19. Isaacs, J. T., Isaacs, W. B., Feitz, W. F., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
20. Beecken, W. D., Fernandez, A., Joussen, A. M., Achilles, E. G., Flynn, E., Lo, K. M., Gillies, S. D., Javaherian, K., Folkman, J., and Shing, Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Cancer Inst. (Bethesda), 93: 382-387, 2001.
21. Bhujwalla, Z. M., Artemov, D., Natarajan, K., Ackerstaff, E., and Solaiyappan, M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia, 3: 143-153, 2001.
22. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein Measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
23. Wang, J., Lou, P., and Henkin, J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J. Cell. Biochem., 77: 465-473, 2000.
24. Rodriguez-Nieto, S., Medina, M. A., and Quesada, A. R. A reevaluation of fumagillin selectivity towards endothelial cells. Anticancer Res., 21: 3457-3460, 2001.
25. Kragh, M., Quistorff, B., Lund, E. L., and Kristjansen, P. E. Quantitative estimates of vascularity in solid tumors by non-invasive near-infrared spectroscopy. Neoplasia, 3: 324-330, 2001.
26. Lund, E. L., Bastholm, L., and Kristjansen, P. E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multi-forme xenografts. Clin. Cancer Res., 6: 971-978, 2000.
27. Kanamori, S., Nishimura, Y., Okuno, Y., Horii, N., Saga, T., and Hiraoka, M. Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor. Int. J. Hyperthermia, 15: 267-278, 1999.